Dr. Lacey was the former research head at Amgen Inc. He played a fundamental role in the discovery of the OPG/RANKL/RANK pathway at Amgen which led to the development of the anti-RANKL human mAb denosumab, an emerging dual blockbuster for both osteoporosis and cancer-related bone diseases. Denosumab has received a number of awards including the US 2011 Prix Galien award for best new biotechnology product and the 2010 Scrip award for best new drug.
Senior Vice President, Discovery Research and Amgen South San Francisco Site Leader, Vice President, Basic Research, Metabolic Disorders, Amgen Inc. (2000-2011).
Senior Director, Department of Pathology/Pathology, Amgen Inc. (1994-2000) Assistant Professor of Pathology, Jewish Washington University Medical Center M.D. University of Colorado.